Ian Haydon, a healthy 29-year-old, reported to a medical clinic in Seattle for a momentous blood draw last week. “Oh yeah,” said the nurse taking his blood. “That is liquid gold.” Haydon is an obscure but important participant in the most consequential race for a vaccine in medical history. In early April, he was among the first people in the United States to receive an experimental vaccine that could help end the coronavirus crisis.
Read more here.
